Acceleron Pharma
Get Full AccessDescription
- Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body's ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company's lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.
-
Headquarters:128 Sidney Street , Cambridge, Massachusetts, United States
More -
Phone Number: +1 617-649-9200
-
Website: https://www.acceleronpharma.com
-
Employees:303
-
Revenue:$250 - 500M
-
Legal Name:Acceleron Pharma
-
Acceleron Pharma's Social Media
-
Is this data correct?
-
| NAICS Code: 325412 |
Show More
Frequently Asked Questions regarding Acceleron Pharma
-
Where are Acceleron Pharma's Headquarters?
Acceleron Pharma's Headquarters are in 128 Sidney Street ,Cambridge,Massachusetts,United States
-
What is Acceleron Pharma's phone number?
Acceleron Pharma's phone number is +1 617-649-9200
-
What is Acceleron Pharma's official website?
Acceleron Pharma's official website is https://www.acceleronpharma.com
-
What is Acceleron Pharma's Revenue?
Acceleron Pharma's revenue is $250 - 500M
-
What is Acceleron Pharma's NAICS code?
Acceleron Pharma's NAICS code is 325412
-
How many employees are working in Acceleron Pharma
Acceleron Pharma has 303 employees
-
What is Acceleron Pharma's Industry?
Acceleron Pharma is in the industry of Biotechnology
-
Who is Acceleron Pharma's CEO?
Acceleron Pharma's CEO is Arslan Gokhan

